Dear colleagues!
On August 28, 2026, the full texts of the new clinical guidelines were published on the official website of the European Society of Cardiology (ESC), dedicated to the issues of cardiovascular diseases and chronic kidney disease.
The provisions of these clinical recommendations were presented to the participants of a number of specially organized scientific sessions, and also served as a reason for active discussions.
Novel GLP-1 Agonist Promotes Safe and Effective Weight Loss
Ecnoglutide, a novel glucagon-like peptide-1 (GLP-1) receptor agonist, was significantly more effective than placebo for inducing weight loss in adults with overweight or obesity, based on data from more than 600 individuals.
The New Playbook for Ditching Dangerous Senior Meds
A new tool presented at the American Geriatrics Society (AGS) 2025 Annual Scientific Meeting may give clinicians practical and safer alternatives to risky medications for patients.
HFA CONFERENCE NEWS June 29 - July 01, 2021, Virtual
IV Iron Can Save Costs in HF With Iron Deficiency in Analysis;
HF Med Undertreatment Due to Older Age Common, Flouts Evidence;
Iron-Clad Benefits of CRT Seen in Reduced-EF Heart Failure;
Assays May Guide SGLT2 Inhibitor Use in High CV-Risk Diabetes
"COVID-19 and cardiovascular diseases: main aspects" The report of Igor S. Yavelov MD, PhD, Professor of cardiology
CV risk factors and CVD are present in many patients with COVID-19 and their presence is associated with an increased risk of cardiovascular complications with new coronavirus infection.
Young adults who lost and then restored heart health had lower risk of heart attack, stroke
A long-term analysis of young adults in Korea found that those with poor heart health had higher rates of cardiovascular disease at a younger age.
EAS Helsinki 2021 Virtual. THE RISE OF CARDIOMETABOLIC DISEASE
Not only are we living in a COVID-19 pandemic, but also an accelerating pandemic of cardiometabolic disease, requiring renewed focus. The third plenary session discussed options to address this escalation in cardiometabolic disease.
COVID-19 vaccine benefits still outweigh risks, despite possible rare heart complications. Statement from the American Heart Association/American Stroke Association
Late last week, the U.S. Centers for Disease Control and Prevention (CDC) alerted health care professionals that they are monitoring the Vaccine Adverse Events Reporting System (VAERS) and the Vaccine Safety Datalink (VSD) for cases of young adults developing the rare heart-related complication myocarditis, after receiving a COVID-19 vaccine manufactured by Pfizer-BioNTech or Moderna.
Administration of patients during and after a coronavirus pandemic. Interview with professor Mekhman N. Mamedov.
Dear Colleagues! On April 27, 2021, at the initiative of the Indonesian Society of Cardiology, an online meeting was held with one of the leading experts of Russia in the cardiology, Professor Mekhman N. Mamedov
Six pregnancy complications are among red flags for heart disease later in life. American Heart Association Scientific Statement
Six pregnancy-related complications - high blood pressure, gestational diabetes, preterm delivery, small-for-gestational-age delivery, pregnancy loss or placental abruption – increase a woman’s risk for developing cardiovascular disease (CVD) later in life, according to a new scientific statement from the American Heart Association, published today in the Association’s flagship journal Circulation.
RU
EN